Sunitinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-SUNITINIB |
|---|---|
| Type | Drug |
| Aliases | SutentСунітиніб |
| Status | reviewed 2026-05-03 | pending_clinical_signoff |
| Diseases | DIS-GIST DIS-PNET |
| Sources | SRC-NCCN-NET-2025 |
Drug Facts
| Class | Multi-targeted receptor tyrosine kinase inhibitor (TKI) |
|---|---|
| Mechanism | Potent inhibitor of multiple receptor tyrosine kinases: VEGFR-1/2/3, PDGFR-α/β, c-KIT, FLT3, CSF-1R, RET. Antiangiogenic + direct antiproliferative effects. In pNET: anti-VEGF/PDGF pathway disrupts tumour neovasculature; direct TKI effect on pNET cells that overexpress VEGFR. Raymond 2011 NEJM: mPFS 11.4 vs 5.5 mo (HR 0.42) in well- differentiated progressive pNET. |
| Typical dosing | 37.5 mg PO once daily continuous (pNET dosing — not the 50 mg on/off 4wk/2wk schedule used in RCC/GIST). Take with or without food. Avoid CYP3A4 strong inhibitors/inducers. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-03 |
Notes
Raymond 2011 NEJM: sunitinib 37.5 mg continuous vs placebo in progressive well-differentiated pNET (n=171). mPFS 11.4 vs 5.5 mo (HR 0.42, p<0.001). Trial stopped early at interim analysis. FDA approved sunitinib for pNET May 2011 (same month as everolimus). Continuous 37.5 mg dosing vs the on/off 50 mg schedule used in RCC: lower peak exposure, improved tolerability, maintained efficacy in pNET. Also approved for imatinib- resistant GIST (2006) and advanced RCC (2006).
Used By
Algorithms
ALGO-PNET-METASTATIC-1L- ALGO-PNET-METASTATIC-1L
Indications
IND-PNET-METASTATIC-1L-EVEROLIMUS- IND-PNET-METASTATIC-1L-EVEROLIMUS
Regimens
REG-SUNITINIB-GIST-2L- Sunitinib monotherapy (GIST 2L; imatinib-resistant/intolerant)REG-SUNITINIB-RCC- Sunitinib (RCC)